^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:Chronic Myeloid Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2019
    Title:

    Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).

    Published date:
    05/26/2019
    Excerpt:
    Pts with CR/CRi vs. those without CR/CRi had higher median number of Ph+ metaphases (100% vs. 32%, p<0.01) and higher baseline BCR-ABL1 PCR (100% vs. 0.5% p=0.01)…TKIs included ponatinib (n=7), dasatinib (n=4), bosutinib (n=1) and nilotinib (n=1)…VEN+TKI combinations show encouraging activity in pre-treated, advanced Ph+ leukemias, particularly CML MBP...
    DOI:
    10.1200/JCO.2019.37.15_suppl.e18515